Logo image of LUNG

PULMONX CORP (LUNG) Stock Price, Quote, News and Overview

NASDAQ:LUNG - Nasdaq - US7458481014 - Common Stock - Currency: USD

3.12  -0.02 (-0.64%)

After market: 3.12 0 (0%)

LUNG Quote, Performance and Key Statistics

PULMONX CORP

NASDAQ:LUNG (5/22/2025, 5:37:42 PM)

After market: 3.12 0 (0%)

3.12

-0.02 (-0.64%)

Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Equipment
Statistics
52 Week High9.37
52 Week Low3.06
Market Cap125.58M
Shares40.25M
Float38.79M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)07-29 2025-07-29/amc
IPO10-01 2020-10-01


LUNG short term performance overview.The bars show the price performance of LUNG in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -20 -40 -60

LUNG long term performance overview.The bars show the price performance of LUNG in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of LUNG is 3.12 USD. In the past month the price decreased by -39.65%. In the past year, price decreased by -61.34%.

PULMONX CORP / LUNG Daily stock chart

LUNG Competitors/Peers

The largest stocks on the US markets in the "Health Care Equipment" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABT ABBOTT LABORATORIES 27.51 228.06B
ISRG INTUITIVE SURGICAL INC 71.03 194.50B
BSX BOSTON SCIENTIFIC CORP 38.7 154.56B
SYK STRYKER CORP 30.19 144.39B
MDT MEDTRONIC PLC 14.71 103.77B
BDX BECTON DICKINSON AND CO 12.23 49.48B
EW EDWARDS LIFESCIENCES CORP 28.77 43.97B
IDXX IDEXX LABORATORIES INC 44.28 40.91B
RMD RESMED INC 27.04 36.00B
DXCM DEXCOM INC 51.41 33.26B
GEHC GE HEALTHCARE TECHNOLOGY 15.1 31.79B
STE STERIS PLC 26.1 23.95B

About LUNG

Company Profile

LUNG logo image Pulmonx Corp. is a medical technology company, which engages in the provision of interventional pulmonology, planning tools and treatments for obstructive lung diseases. The company is headquartered in Redwood City, California and currently employs 291 full-time employees. The company went IPO on 2020-10-01. The firm provides minimally invasive treatments for chronic obstructive pulmonary disease (COPD). The Company’s Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX Platform, and StratX Lung Analysis Report are designed to assess and treat patients with severe emphysema/COPD. The LungTraX Platform is a cloud-based quantitative CT (QCT) analysis service that provides physicians with multiple products, LungTraX Connect, to improve workup efficiency, LungTraX Detect, to enable patient identification and an easy-to-read StratX Lung report that it designed for its solution that includes information on emphysema destruction, fissure completeness and lobar volume to help identify target lobes for treatment with Zephyr Valves. The Chartis System is a proprietary balloon catheter and console system with flow and pressure sensors designed to assess the presence of collateral ventilation.

Company Info

PULMONX CORP

700 Chesapeake Dr

Redwood City CALIFORNIA 94063 US

CEO: Glendon E. French

Employees: 291

LUNG Company Website

LUNG Investor Relations

Phone: 16509342600

PULMONX CORP / LUNG FAQ

What is the stock price of PULMONX CORP today?

The current stock price of LUNG is 3.12 USD. The price decreased by -0.64% in the last trading session.


What is the ticker symbol for PULMONX CORP stock?

The exchange symbol of PULMONX CORP is LUNG and it is listed on the Nasdaq exchange.


On which exchange is LUNG stock listed?

LUNG stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for PULMONX CORP stock?

13 analysts have analysed LUNG and the average price target is 11.88 USD. This implies a price increase of 280.63% is expected in the next year compared to the current price of 3.12. Check the PULMONX CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is PULMONX CORP worth?

PULMONX CORP (LUNG) has a market capitalization of 125.58M USD. This makes LUNG a Micro Cap stock.


How many employees does PULMONX CORP have?

PULMONX CORP (LUNG) currently has 291 employees.


What are the support and resistance levels for PULMONX CORP (LUNG) stock?

PULMONX CORP (LUNG) has a resistance level at 3.71. Check the full technical report for a detailed analysis of LUNG support and resistance levels.


Is PULMONX CORP (LUNG) expected to grow?

The Revenue of PULMONX CORP (LUNG) is expected to grow by 17.78% in the next year. Check the estimates tab for more information on the LUNG EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy PULMONX CORP (LUNG) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does PULMONX CORP (LUNG) stock pay dividends?

LUNG does not pay a dividend.


When does PULMONX CORP (LUNG) report earnings?

PULMONX CORP (LUNG) will report earnings on 2025-07-29, after the market close.


What is the Price/Earnings (PE) ratio of PULMONX CORP (LUNG)?

PULMONX CORP (LUNG) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.4).


What is the Short Interest ratio of PULMONX CORP (LUNG) stock?

The outstanding short interest for PULMONX CORP (LUNG) is 3.08% of its float. Check the ownership tab for more information on the LUNG short interest.


LUNG Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

LUNG Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to LUNG. LUNG has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

LUNG Financial Highlights

Over the last trailing twelve months LUNG reported a non-GAAP Earnings per Share(EPS) of -1.4. The EPS increased by 9.09% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -37.88%
ROE -73.51%
Debt/Equity 0.38
Chartmill High Growth Momentum
EPS Q2Q%0%
Sales Q2Q%19.54%
EPS 1Y (TTM)9.09%
Revenue 1Y (TTM)19.84%

LUNG Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 80% to LUNG. The Buy consensus is the average rating of analysts ratings from 13 analysts.

For the next year, analysts expect an EPS growth of -11.57% and a revenue growth 17.78% for LUNG


Ownership
Inst Owners94.24%
Ins Owners4.75%
Short Float %3.08%
Short Ratio3.32
Analysts
Analysts80
Price Target11.88 (280.77%)
EPS Next Y-11.57%
Revenue Next Year17.78%